0 0

0 0

In this interview, Prasad Raje, CEO of LGM Pharma, explains how LGM’s API sourcing, CDMO and analytical services work together to take products from development to commercial launch, and how recent shocks have reshaped supply‑chain strategy, from onshoring and diversification to investments in patient‑proximate manufacturing and women’s‑health dosage forms.

1 0

In this interview, CDMO Martin and Arul reflect on how the contract development and manufacturing industry has matured over the past decade—from nimble responses and new modalities to commercial-scale technologies—and how it’s poised to accelerate specialized therapies, speed drugs to patients, and partner more closely with pharma. They discuss COVID’s catalytic role, the shift from high-volume to targeted medicines, and why manufacturing’s precision and foresight (Batman’s gadgets) are now central to turning breakthrough science into real treatments.

2 1

In this interview, Axplora’s leadership discusses recent multi‑million euro investments, from GLP‑1 capacity in Mourenx to high‑potency API and ADC capabilities at Gropello Cairoli and LeMans, and how those moves align with market trends. They explain the company’s data‑driven, track‑record‑led strategy to scale complex ADC and HPAPI manufacturing, accelerate clinical supply without adding risk, and deliver an integrated, end‑to‑end offering for customers and patients.

1 0

In this interview we spoke with Andy Burns, VP at Kindeva Drug Delivery, about MDIs, sustainable propellants, and their new Loughborough Centre of Excellence. Watch the full DCAT Week 2026 interview.

1 0

During #dcatweek we had a great chat with Himanshu Gadgil, CEO of Enzene Biosciences Ltd. We talked about making biologic medicines more affordable with their Enzene X continuous manufacturing approach, bringing that tech to New Jersey (and even animal health), and how real‑time analytics + AI could change how medicines are made. Honest, practical conversation, give it a watch.

#interview #biopharma #biotech #biologic #ai #medicines #biosimilars #manufacturing #technologies #innovation #investment

3 0

Ken from Grifols, 16 years at the plasma company, discusses his move from bioscience to tech and CDMO work, how Grifols leverages plasma expertise for contract manufacturing, and plans to grow U.S. IV solutions.

0 0